A LinkedIn post from Phantom Neuro indicates the company plans to participate in The Montgomery Summit 2026 next month, where its founder and CEO, Connor Glass, is scheduled to present. The post highlights Phantom X, described as a minimally invasive neural interface placed beneath the skin that decodes muscle signals and uses artificial intelligence to enable intuitive control of prosthetic limbs.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, the presentation will focus on Phantom X’s reported high-accuracy, low-latency decoding of hand and wrist movements in real time, positioning the technology as part of a broader shift in human–machine interaction. For investors, visibility at a high-profile tech and healthcare conference could enhance Phantom Neuro’s exposure to potential partners and capital, while the emphasis on AI-driven neurotechnology suggests a focus on differentiated intellectual property in the prosthetics and neurotech markets.
The event is scheduled for Wednesday, March 11, 2026, in Santa Monica, California, with a dedicated 30-minute presentation slot, which may provide additional validation if the technology resonates with an audience of investors and industry strategics. While the post is promotional in nature and does not disclose financial metrics or commercial timelines, it underscores Phantom Neuro’s efforts to position Phantom X as a platform technology in AI-enabled healthcare and human–machine interfaces, areas that have attracted increasing venture and strategic interest.